Element Pointe Advisors LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Element Pointe Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,968 shares of the medical device company's stock, valued at approximately $309,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Forvis Mazars Wealth Advisors LLC boosted its holdings in DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. boosted its stake in shares of DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Level Four Advisory Services LLC increased its position in shares of DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares during the last quarter. Finally, Covestor Ltd grew its stake in DexCom by 15.6% in the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the topic of a number of research analyst reports. Barclays boosted their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Mizuho began coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price for the company. Canaccord Genuity Group boosted their price objective on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $98.11.

DexCom Stock Up 1.7 %

DexCom stock opened at $81.62 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The company has a market cap of $32.00 billion, a PE ratio of 57.07, a PEG ratio of 2.30 and a beta of 1.43. The business's 50-day simple moving average is $71.15 and its two-hundred day simple moving average is $76.96.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last three months. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.